0GRZ.LSE RaySearch Laboratories AB ser. B
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is 0GRZ.LSE undervalued?
Graham numberThe Graham number of RaySearch Laboratories AB ser. B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RaySearch Laboratories AB ser. B fundamental analysis
No fundamental analysis for RaySearch Laboratories AB ser. B yet.
RaySearch Laboratories AB ser. B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RaySearch Laboratories AB ser. B
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning a…
Full company profileRaySearch Laboratories AB ser. B financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
RaySearch Laboratories AB ser. B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 531M | 585M | 627M | 742M | 652M | - | - | - |
| Gross Profit | 505M | 548M | 571M | 669M | 608M | - | - | - |
| Operating Income | 200M | 160M | 94.5M | 68.2M | -3.47M | - | - | - |
| Net Income | 151M | 118M | 78.5M | 50.4M | -9.08M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | - | - | - | 1.26B | 1.28B | - | - | - |
| Total Liabilities | - | - | - | 559M | 591M | - | - | - |
| Shareholders' Equity | - | - | - | 705M | 694M | - | - | - |
| Cash & Short-term Investments | - | - | - | 114M | 169M | - | - | - |
| Total Debt | - | - | - | 85.8M | 53.8M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 121M | 147M | 178M | 320M | 332M | 238M | 373M | - |
| Capital Expenditure | 107M | 149M | 73.3M | 47.2M | 29.7M | 52.0M | 0.00 | 0.00 |
| Ratios | ||||||||
| ROE | - | - | - | 7.1% | -1.3% | - | - | - |
| ROA | - | - | - | 4.0% | -0.7% | - | - | - |
| Net Profit Margin | 28.5% | 20.1% | 12.5% | 6.8% | -1.4% | - | - | - |
| Debt to Equity | - | - | - | 0.12x | 0.08x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RaySearch Laboratories AB ser. B dividends
RaySearch Laboratories AB ser. B has not paid dividends in the last 9 fiscal years.
Last stock split: 3.00003:1 on Jun 25, 2008.
Who owns RaySearch Laboratories AB ser. B
- Insiders 10.85%
- Institutions 57.61%
- Public & others 31.54%
- Free float 27.4M
RaySearch Laboratories AB ser. B company profile
- Company name
- RaySearch Laboratories AB ser. B
- Ticker
- 0GRZ.LSE
- ISIN
- SE0000135485
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 464
- Fiscal year end
- December
- Address
- EugeniavAegen 18 C, Stockholm, Sweden, 113 68
- Phone
- 46 8 51 05 30 00
- Website
- raysearchlabs.com
About RaySearch Laboratories AB ser. B
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; Machine Learning; and Liver Ablation Solutions. The company was founded in 2000 and is headquartered in Stockholm, Sweden.
RaySearch Laboratories AB ser. B management
10- Dr. Johan Lof Ph.D.Founder, CEO, President & Director · born 1969
- Mr. Bjorn HardemarkDeputy Chief Executive Officer · born 1977
- Ms. Nina GrönbergChief Financial Officer · born 1978
- Mr. Kjell ErikssonChief Science Officer · born 1973
- Ms. Carolina Haglund StromlidHead of Investor Relations · born 1972
- Ms. Petra JanssonGeneral Counsel · born 1973
- Ms. Jenna StyanDirector of Corporate Development & Strategy
- Ms. Tove AlteborgGlobal Human Resource Manager · born 1980
- Mr. Fredrik LofmanHead of Machine Learning · born 1978
- Laura AntonovicHead of Strategic Partnerships & RaySearch Laboratories